- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | Ipsen rises after cancer treatment drives Q1 beat | 1 | Reuters | ||
| 24.04. | Ipsen S.A. reports Q1 results; reaffirms full-year guidance | 1 | Seeking Alpha | ||
| 24.04. | Ipsen Q1 Total-sales Up 13.3% At CER; Confirms 2024 Financial Guidance | 1 | RTTNews | ||
| 24.04. | Ipsen Pharma: Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance | 206 | GlobeNewswire (Europe) | PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
? ? Q1 2024? Q1 2023?... ► Artikel lesen | |
| 24.04. | Ipsen und Skyhawk Therapeutics geben Zusammenarbeit bei der Erforschung seltener neurologischer Erkrankungen durch RNA-Targeting bekannt | 332 | news aktuell | Paris und Boston (ots/PRNewswire) - - Ipsen schließt eine Optionsvereinbarung ab, um exklusive globale Rechte an zwei Kandidaten zu erhalten, die im Rahmen der Zusammenarbeit verfolgt werden- Nach der... ► Artikel lesen | |
| 23.04. | Ipsen and Skyhawk partner to develop rare neurological therapies | 1 | Pharmaceutical Technology | ||
| 22.04. | Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases | 2 | BioPharma Dive | ||
| 22.04. | Ipsen and Skyhawk Therapeutics Collaborate on RNA Targeting Research | 2 | Contract Pharma | ||
| 22.04. | Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies | 1 | PMLiVE | ||
| 22.04. | Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D | 3 | FierceBiotech | ||
| 22.04. | Ipsen signs $1.8bn RNA drug alliance with Skyhawk | - | pharmaphorum | ||
| 22.04. | Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases | 2 | Seeking Alpha | ||
| 22.04. | Ipsen, Skyhawk Therapeutics To Develop RNA-Modulating Molecules For Rare Neurological Disorders | 1 | RTTNews | ||
| 22.04. | Ipsen Pharma: Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases | 250 | GlobeNewswire (Europe) | Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaborationFollowing development candidate validation, Ipsen will assume responsibility... ► Artikel lesen | |
| 19.04. | Ipsen announces launch of new UK headquarters in London life sciences community | 1 | PMLiVE | ||
| 17.04. | Ipsen Pharma: Ipsen publishes its 2023 Universal Registration Document | 2 | GlobeNewswire (USA) | ||
| 03.04. | Ipsen Joins the ADC Chase, Licensing Phase 1-Ready Asset for Novel Cancer Target | 2 | MedCity News | ||
| 02.04. | Ipsen joins the ADC club with deal worth up to $900m | 1 | Pharmaceutical Technology | ||
| 02.04. | Ipsen joins ADC race via $900M biobuck deal with Sutro, chasing same target as Merck, Boehringer | 5 | FierceBiotech | ||
| 02.04. | Ipsen enters $900m licensing agreement for Sutro Biopharma's ADC candidate | 2 | PMLiVE |
Seite:
1 2 3 4 5 Weiter >>
95 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IM CANNABIS CORP | 1,160 | 0,00 % | Pre-market Movers: IMCC, CVRX, TGTX, ROOT, PLTN. | WOONSOCKET (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 09.00 A.M. ET).In the Green IM Cannabis Corp. (IMCC) is up over 36% at $0.86.
TG... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,365 | 0,00 % | Aquestive stock falls amid Libervant approval, Anaphylm update | ||
| LYRA THERAPEUTICS | 5,270 | +2,13 % | Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory... ► Artikel lesen | |
| HARROW | 10,410 | 0,00 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| OMNIAB | 4,545 | +2,36 % | OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program... ► Artikel lesen | |
| NEUROGENE | 33,730 | 0,00 % | Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 0,860 | 0,00 % | Pre-market Movers: Zhongchao, Redwoods Acquisition Corp., Tritium DCFC, Nexalin Technology, Sunshine Biopharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.05 A.M. ET).In the Green Zhongchao Inc. (ZCMD) is up over 96% at $2.83.
Redwoods... ► Artikel lesen | |
| SOLID BIOSCIENCES | 9,540 | 0,00 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases... ► Artikel lesen | |
| ITERUM THERAPEUTICS | 1,590 | +3,25 % | Iterum Therapeutics PLC: Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | --First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 3,260 | +6,54 % | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen | |
| PROCESSA PHARMACEUTICALS | 2,220 | 0,00 % | Pre-market Movers: Barfresh Food, Processa Pharmaceuticals, reAlpha Tech, Biophytis, Meta Platforms | ARMONK (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Barfresh Food Group, Inc. (BRFH) is up over 96% at... ► Artikel lesen | |
| ELEVAI LABS | 0,678 | 0,00 % | Elevai Labs Inc.: Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments | ||
| INTERCURE | 2,960 | 0,00 % | InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million | NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts... ► Artikel lesen | |
| ALLARITY THERAPEUTICS | 1,370 | 0,00 % | Allarity Therapeutics, Inc.: Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement | Boston (April 29, 2024) - Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,... ► Artikel lesen | |
| BIONANO GENOMICS | 0,970 | +9,83 % | Bionano Genomics: Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing | SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping... ► Artikel lesen |
IPSEN SA ADR gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 26,800 Euro und damit -1,47 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
